663 related articles for article (PubMed ID: 30170949)
1. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.
Chow CK; Ramasundarahettige C; Hu W; AlHabib KF; Avezum A; Cheng X; Chifamba J; Dagenais G; Dans A; Egbujie BA; Gupta R; Iqbal R; Ismail N; Keskinler MV; Khatib R; Kruger L; Kumar R; Lanas F; Lear S; Lopez-Jaramillo P; McKee M; Mohammadifard N; Mohan V; Mony P; Orlandini A; Rosengren A; Vijayakumar K; Wei L; Yeates K; Yusoff K; Yusuf R; Yusufali A; Zatonska K; Zhou Y; Islam S; Corsi D; Rangarajan S; Teo K; Gerstein HC; Yusuf S;
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):798-808. PubMed ID: 30170949
[TBL] [Abstract][Full Text] [Related]
2. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
[TBL] [Abstract][Full Text] [Related]
3. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Attaei MW; Khatib R; McKee M; Lear S; Dagenais G; Igumbor EU; AlHabib KF; Kaur M; Kruger L; Teo K; Lanas F; Yusoff K; Oguz A; Gupta R; Yusufali AM; Bahonar A; Kutty R; Rosengren A; Mohan V; Avezum A; Yusuf R; Szuba A; Rangarajan S; Chow C; Yusuf S;
Lancet Public Health; 2017 Sep; 2(9):e411-e419. PubMed ID: 29253412
[TBL] [Abstract][Full Text] [Related]
4. Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia.
Kaiser AH; Hehman L; Forsberg BC; Simangolwa WM; Sundewall J
PLoS One; 2019; 14(12):e0226169. PubMed ID: 31834889
[TBL] [Abstract][Full Text] [Related]
5. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India.
Satheesh G; Sharma A; Puthean S; Ansil T P M; E J; Raj Mishra S; Unnikrishnan MK
Trop Med Int Health; 2020 Dec; 25(12):1467-1479. PubMed ID: 32959441
[TBL] [Abstract][Full Text] [Related]
6. The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries.
Babar ZU; Ramzan S; El-Dahiyat F; Tachmazidis I; Adebisi A; Hasan SS
Front Pharmacol; 2019; 10():1375. PubMed ID: 31824316
[No Abstract] [Full Text] [Related]
7. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.
Ewen M; Zweekhorst M; Regeer B; Laing R
PLoS One; 2017; 12(2):e0171284. PubMed ID: 28170413
[TBL] [Abstract][Full Text] [Related]
8. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
9. Evaluating access to oral anti-diabetic medicines: A cross-sectional survey of prices, availability and affordability in Shaanxi Province, Western China.
Yang C; Hu S; Zhu Y; Zhu W; Li Z; Fang Y
PLoS One; 2019; 14(10):e0223769. PubMed ID: 31618273
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of availability, price, and affordability of cardiovascular, diabetes, and global medicines in Abuja, Nigeria.
Osuafor NG; Ukwe CV; Okonta M
PLoS One; 2021; 16(8):e0255567. PubMed ID: 34383799
[TBL] [Abstract][Full Text] [Related]
11. Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study.
Miller V; Yusuf S; Chow CK; Dehghan M; Corsi DJ; Lock K; Popkin B; Rangarajan S; Khatib R; Lear SA; Mony P; Kaur M; Mohan V; Vijayakumar K; Gupta R; Kruger A; Tsolekile L; Mohammadifard N; Rahman O; Rosengren A; Avezum A; Orlandini A; Ismail N; Lopez-Jaramillo P; Yusufali A; Karsidag K; Iqbal R; Chifamba J; Oakley SM; Ariffin F; Zatonska K; Poirier P; Wei L; Jian B; Hui C; Xu L; Xiulin B; Teo K; Mente A
Lancet Glob Health; 2016 Oct; 4(10):e695-703. PubMed ID: 27567348
[TBL] [Abstract][Full Text] [Related]
12. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
Zhu Y; Wang Y; Sun X; Li X
Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
[TBL] [Abstract][Full Text] [Related]
13. Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji.
Huang Y; Jiang Y; Zhang L; Mao W; van Boven JFM; Postma MJ; Chen W
BMC Health Serv Res; 2018 Mar; 18(1):218. PubMed ID: 29587742
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
15. Access to essential medicines for diabetes care: availability, price, and affordability in central Ethiopia.
Deressa HD; Abuye H; Adinew A; Ali MK; Kebede T; Habte BM
Glob Health Res Policy; 2024 Apr; 9(1):12. PubMed ID: 38584277
[TBL] [Abstract][Full Text] [Related]
16. Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study.
Dzudie A; Njume E; Abanda M; Aminde L; Hamadou B; Dzekem B; Azabji M; Doualla MS; Ngowe M; Kengne AP
PLoS One; 2020; 15(3):e0229307. PubMed ID: 32130252
[TBL] [Abstract][Full Text] [Related]
17. Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.
Moye-Holz D; Ewen M; Dreser A; Bautista-Arredondo S; Soria-Saucedo R; van Dijk JP; Reijneveld SA; Hogerzeil HV
BMC Health Serv Res; 2020 May; 20(1):424. PubMed ID: 32410676
[TBL] [Abstract][Full Text] [Related]
18. Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study.
Kibirige D; Atuhe D; Kampiire L; Kiggundu DS; Donggo P; Nabbaale J; Mwebaze RM; Kalyesubula R; Lumu W
Int J Equity Health; 2017 Aug; 16(1):154. PubMed ID: 28836972
[TBL] [Abstract][Full Text] [Related]
19. A national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri Lanka.
Dabare PR; Wanigatunge CA; Beneragama BH
BMC Public Health; 2014 Aug; 14():817. PubMed ID: 25103467
[TBL] [Abstract][Full Text] [Related]
20. Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study.
Sarayani A; Rashidian A; Gholami K
BMJ Open; 2014 Oct; 4(10):e005859. PubMed ID: 25324322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
